Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Ajou University School of Medicine

Status: Not yet enrolling

Conditions: Cerebral Infarction; Dipeptidyl-Peptidase IV Inhibitors; Infarction, Brain

Treatments: Drug: Dipeptidyl peptidase-4 inhibitor

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05817097

AJOUIRB-EX-2023-089

Details and patient eligibility

About

The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction.

Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.

Full description

This is a retrospective study to see the effects of reducing the severity of cerebral infarction(requiring thrombolysis or endovascular recanalization) of DPP-4 inhibitors by comparing the survival rate after acute cerebral infarction hospitalization, discharge rate to home, and medical cost.

A. Severity of cerebral infarction and poor prognosis is mainly associated with hyperglycemia caused by diabetes, which increases the Infarction volume and hemorrhagic trasformation.

B. However, the effect of loergin blood glucose on reducing the Infarction volume and improving prognosis of cerebral infarction has not been proven.

C. Preclinical studies have demonstrated a anti-stroke effect that reduces the Infarction volume using certain anti-diabetic drugs.

D. Therefore, there is a possibility that certain anti-diabetic drugs may reduce the severity of cerebral infarction as a class effect in addition to the effect of blood sugar control.

E. This is particularly likely to exist in the DPP-4 inhibitor family identified through preclinical studies.

Enrollment: 22,119 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute cerebral infarction who underwent thrombolysis or endovascular recanalization in Korea between 2014 and 2021

• Those who have been previously diagnosed with diabetes and are taking oral anti-diabetic drugs

• Adult (over 19 years of age)

  • The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.

Exclusion criteria

• Patients taking insulin to control diabetes

Trial design

22,119 participants in 2 patient groups

DPP4i

Description:

used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization) Combination therpay is acceptable.

Treatment:

Drug: Dipeptidyl peptidase-4 inhibitor

except DPP4i

Description:

patients that did not use DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction(requiring thrombolysis or endovascular recanalization)